You are here

What is the prevalence of CVD in patients with prostate cancer and how do we assess CV risk when deciding treatment strategy?

Alexander Lyon

Lyons senza slides-HD

Dr Lyon presents data showing that the risk of cardiovascular events and new onset diabetes is increased by treatment with GnRH agonists, but GnRH antagonists may provide an option with less cardiovascular toxicity. During treatment of prostate cancer, cardiovascular health should be optimized and cardiovascular risk should guide treatment strategies.